PFM Health Sciences’s Merck MRK Stock Holding History

PFM Health Sciences’s Portfolio MRK Stock Details MRK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-2,506,921	Closed	-$138M	–	99
2016 Q2	$138M	Buy	+2,506,921	New	+$133M	4.16%	1
2015 Q4	–	Sell	-1,363,762	Closed	-$1.75M	–	80
2015 Q3	$1.75M	Buy	+1,363,762	New	+$72.4M	0.05%	64

Other funds holding MRK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PFM Health Sciences's MRK Position: Q1 2026 in Review

PFM Health Sciences sold out of Merck (MRK) in Q1 2026, closing a stake of 187,834 shares — an estimated $19.8M sold.

PFM Health Sciences first reported a position in MRK in Q2 2013 and held it in 17 quarters. The position peaked at $88.6M in Q2 2022. 3,777 funds tracked by Wall St. Rank hold MRK as of Q1 2026.

PFM Health Sciences reported no remaining Merck position as of Q1 2026 after selling out during the quarter.
PFM Health Sciences sold 187,834 Merck shares in Q1 2026, an estimated $19.8M.
PFM Health Sciences first reported a position in Merck in Q2 2013 and held it in 17 quarters.
PFM Health Sciences's Merck position peaked at $88.6M in Q2 2022.
3,777 funds tracked by Wall St. Rank held Merck as of Q1 2026.

Based on PFM Health Sciences's 13F filing for Q1 2026, filed 15 May 2026.